Research company Peptonic Medical states that the acquisition of a stake in DGH International, formerly Intellego Technologies, is a strategic investment and does not change the existing operations. The purchase was financed with loans. "The acquisition was financed through the raising of loans. Loans from the sellers, ScanInvest and Bosmac Invest, amount to SEK 4.5 million each, run until further notice with monthly interest of 1 percent, with the possibility of being fully or partially offset against newly issued shares in Peptonic at a later date. The seller Mangold Fondkommission was paid SEK 2.4 million in cash and SEK 1.1 million in deferred payment, with a due date of December 31, 2026. To finance the purchase, loans were also taken out from Bizcap and Aramia in the amount of SEK 1.5 million each, with monthly interest of 2 percent and a due date of February 28, 2027," Peptonic writes, but also: "Through the investment, Peptonic obtains an ownership stake in DGH and its underlying operations, including Daro Group International, as well as the technology, IP and patent portfolio within the group. Peptonic's board of directors has assessed that these assets have significant long-term value and that the investment, despite identified risks, offers considerable potential. Furthermore, the board assesses that the underlying values in the DGF group can be further developed or realized in order to create value for Peptonic's shareholders over time".